NSE ScannerPharmaceuticals · Biotechnology · NSE: AKUMS · data 2026-10-31
Akums Drugs and Pharmaceuticals Limited
In plain words
Price: 12.8% below its 52-week high of ₹838.8.
Delivery: 51.9% of traded shares were kept for delivery over the last 10 sessions, against 51.5% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹4,502 cr |
| Net profit (last 12 months) | ₹292 cr |
| Sales growth, 3 years (yearly) | 6.0% |
| Profit growth, 3 years (yearly) | 39.1% |
At a glance
Promoters 75.3% (unchanged in a year), pledged 0.0%, institutions 15.6%.
P/E 38.4, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 8.0%, ROCE 9.8%, operating margin 9.1%: how much profit it earns on the money it uses.
Debt/equity 0.05, Profit growth 39.1% and sales growth 6.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Profit grew 39.1% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
14/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 51.5% over the last 20 sessions vs 47.6% in the 40 before (1.08x); shares delivered per day 0.56x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 1 scheme hold it, about ₹111 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 8 Aug 26Results Results board meeting +4.7% next session
- 3 Jul 26Dividend Dividend ₹1 (ex-date) -2.0% next session
- 14 May 26Results Results board meeting -4.3% next session
- 13 Feb 26Results Results board meeting +2.8% next session
- 13 Nov 25Results Results board meeting -6.4% next session
- 8 Aug 25Results Results board meeting -2.3% next session
- 26 May 25Results Results board meeting +2.0% next session
- 6 Feb 25Results Results board meeting -1.6% next session
- 9 Nov 24Results Results board meeting -10.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% |
| Foreign institutions (FII) | 4.50% | 1.91% | 1.37% | 1.15% |
| Domestic institutions (DII) | 11.08% | 13.44% | 14.35% | 14.40% |
| Mutual funds | 7.58% | 9.77% | 10.95% | 11.23% |
| Retail investors | 4.90% | 5.26% | 5.05% | 5.22% |
| Number of shareholders | 67,618 | 70,289 | 72,589 | 76,869 |
Common questions
How much do promoters hold in Akums Drugs and Pharmaceuticals Limited?
Promoters held 75.26% of Akums Drugs and Pharmaceuticals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Akums Drugs and Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.05, which is very low.
What is Akums Drugs and Pharmaceuticals Limited's P/E ratio?
About 38.4, based on the last 12 months' earnings and a price of ₹731.7 (data 2026-10-31).
What is the 52-week high and low of Akums Drugs and Pharmaceuticals Limited?
The 52-week high is ₹838.8 and the 52-week low is ₹409.3.
Mutual funds holding Akums Drugs and Pharmaceuticals Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹111 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.21% | ₹111 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | ₹731.7 | ₹11,520 cr | 38.4 | — | 8% | 9.8% | 0.05 | +55.4% |
| Anthem Biosciences Limited | ₹828.8 | ₹46,685 cr | 81.7 | — | 21.7% | 26% | 0.02 | +13.6% |
| Rubicon Research Limited | ₹1,610.5 | ₹26,650 cr | 92.7 | — | 27% | 32.4% | 0.24 | +168.0% |
| Fermenta Biotech Ltd | ₹417.55 | ₹1,229 cr | 20.2 | — | 18.7% | 20.8% | 0.28 | +34.7% |
| Fabtech Technologies Limited | ₹123.9 | ₹547 cr | 14.1 | 1.3 | 12.9% | 9.1% | 0.17 | -48.7% |
| Haleos Labs Ltd. | ₹1,394.4 | ₹411 cr | 26.7 | — | 8.4% | 10.4% | 0.52 | +22.2% |
Compare AKUMS with ANTHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AKUMS in NSE Scanner →